Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia

• Published in: Journal of antimicrobial chemotherapy Vol. 78; no. 12; pp. 2938 - 2942
• Main Authors: Djiyou, Armando B D, Penda, Calixte I, Madec, Yoann, Ngondi, Grace D, Moukoko, Astrid, Eboumbou, Carole E, Aghokeng, Avelin F
• Format: Journal Article
• Language: English
• Published: England Oxford University Press (OUP) 01-12-2023
• Subjects: Adolescent; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Cameroon - epidemiology; Drug Resistance, Viral - genetics; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV-1 - genetics; Humanities and Social Sciences; Humans; Prevalence; Viral Load; Viremia - drug therapy; Viremia - epidemiology; Cameroon
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkad334

To characterize HIV drug resistance (HIVDR) below and above the WHO threshold of 1000 copies/mL, considered for the definition of HIV ART failure in resource-limited settings.
From a cohort of 280 adolescents (aged 10-19 years) receiving ART for at least 6 months, genotypic resistance testing (GRT) was attempted for two groups of participants: participants with low-level viraemia [LLV; viral load (VL) 200-999 copies/mL] and those in virological failure (VF; confirmed VL ≥1000 copies/mL) using an in-house method. The Stanford HIValg Program was used to identify relevant HIVDR mutations and predict the efficacy of the newly introduced tenofovir-lamivudine-dolutegravir combination.
GRT was successfully performed in 54/58 (93.1%) eligible participants, of which 28/31 (90.3%) were in VF and 26/27 (96.3%) had LLV. A high level of resistance was found both in adolescents with LLV and those in VF, with respectively 84.6% (22/26) and 75.0% (21/28) of participants harbouring at least one HIVDR mutation. NRTIs and NNRTIs were the most affected drug classes in both population groups. In contrast, PIs were not significantly affected and dolutegravir was expected to be active for all participants tested. However, for the newly introduced dolutegravir-based combination, functional monotherapy (dolutegravir only) was potentially possible for 22.7% (5/22) of the participants with LLV.
Our findings show that the 1000 copies/mL threshold is not an indicator of virological success and we call for a revision of the current WHO definition of VF in resource-limited countries.